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ABSTRACT: Injectable fillers mainly aim to augment tissue
volume and correct wrinkles in cosmetic and plastic
reconstructions. However, the development of long-lasting,
injectable fillers with minimal complications of pain, toxicity,
and displacement has been challenging because of the absence
of reliable cross-linking chemistry. Here, we report a novel
cross-linker-free injectable hydrogel formulated by autoxidation
as a highly biocompatible, easily injectable, and long-term
volumetrically stable filler agent. Self-cross-linkable hyaluronic
acid (SC-HA) with gallol moieties could form a hydrogel via
autoxidation of gallols in vivo without additional cross-linking
agents. The gelation of SC-HA in situ after injection is
accelerated by the self-production of oxygen species and
endogenous peroxidase in vivo. The SC-HA filler does not require a high injection force, thus minimizing pain, bleeding,
and tissue damage-associated complications. In addition, improved tissue adhesiveness of the SC-HA hydrogel by oxidized
gallols (shear strength; 2 kPa) prevented displacement of the filler constructs from the injection site. The SC-HA filler retained
its mechanical properties in vivo (600−700 Pa) for wrinkle correction and volumetric augmentation up to 1 year after injection.
Overall, the performance of the SC-HA hydrogel as an injectable dermal filler was superior to that of commercially available,
chemically cross-linked biphasic HA filler composites in terms of injectability, tissue adhesiveness, and long-term volumetric
augmentation. Our injectable HA hydrogel with no need of cross-linkers provides a long-lasting filler that has clinical utility for
cosmetic applications.
■ INTRODUCTION
Hydrogels have diverse applications in biomedical engineering
fields, which include drug delivery, surface modification, tissue
adhesives, and tissue engineering scaffolds.1−3 In particular,
injectable hydrogels accommodate facile and minimally
invasive procedures for site-directed implantation of three-
dimensional constructs.4−6 With the huge interest in antiaging
and cosmetic applications, the market for injectable fillers
composed of polymeric hydrogels has exponentially increased
in recent years. Filler composites can be utilized for cosmetic
purposes, for volumetric recovery after loss or resection of soft
tissues,7,8 and for the medical treatment of human
immunodeficiency virus-associated facial lipoatrophy.9,10 Re-
cent advances in material science and clinical techniques have
provided diverse options for volumetric tissue augmentation.
Injectable bulking agents made of various synthetic and natural
polymers, such as silicon, polycaprolactone, calcium hydrox-
yapatite, collagen, and decellularized matrix, have been used
clinically.11−14 However, long-term inflammation, allergic
reactions, and rapid degradation due to weak mechanical
properties have limited the widespread use of the current
materials as filler composites.15−18
Hyaluronic acid (HA), a primary component of extracellular
matrices in skin and various connective tissues, is regarded as
one of the best ingredients to fabricate injectable fillers owing
to its biocompatibility and low immunogenicity.19−21 In
addition, HA-based fillers can be removed through enzymatic
degradation using hyaluronidase when unexpected events, such
as displacement and side effects, occur.19,20 HA-based filler
composites can be categorized into monophasic and biphasic
types, according to their chemical and physical formulation.
Monophasic HA fillers can be homogeneously injected, but
they usually show a low volumetric augmentation effect and
short retention time due to their weak mechanical proper-
ties.22−24 Although the mechanical stability of monophasic HA
fillers can be improved by increasing the cross-linking density
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and molecular weight of the composites, a larger-size needle is
required to compensate for the higher extrusion force during
injection by the increased viscosity, which is closely related to
acute pain.25,26 In contrast, biphasic HA fillers containing
specific size cross-linked HA particulates with noncross-linked
HA solution maintain better stability in vivo.24 Chemically
cross-linked particulates of biphasic fillers provide enhanced
elasticity and better performance in volume maintenance
compared with monophasic fillers, but they often form
inhomogeneous shapes that roughen the injection site and
are prone to displacement due to the weak polymeric network
within the composite.27,28 In addition, chemical reagents for
HA cross-linking, such as glutaraldehyde, butanediol-diglycidyl
ether (BDDE), 1,2,7,8-diepoxyoctane, and divinyl sulfone, can
pose safety concerns involving inflammation, foreign body
reaction, and toxicity after injection.29,30 Therefore, there is a
huge need to develop an advanced cross-linking system that
provides a safe, long-lasting, and highly usable filler composite.
In this study, we developed an self-cross-linkable HA (SC-
HA) filler without cross-linkers to overcome rheological and
physiological limitations and safety issues of the current HA
cross-linking systems. The SC-HA hydrogel was prepared by
adopting the phenolic oxidation process to HA polymerization.
Inspired by the strong underwater adhesion and rapid self-
regeneration of marine organisms, phenolic compounds have
been widely used in cross-linking chemistry to develop
functional hydrogel systems for various biomedical applica-
tions.31−35 In particular, the gallol moiety that contains three
hydroxyl groups on the benzene ring generates a dimerized
form of intermediates during the oxidation process, leading to
spontaneous cross-linking and high affinity to various
proteins.36−38 In addition, previous studies have reported
that the strong oxidative property of the gallol group induces
rapid gelation kinetics, especially when catalysts (e.g., sodium
hydroxide, sodium periodate, peroxide) are supplemented
during the cross-linking process.39,40 Therefore, we assumed
that a gallol-modified-HA conjugate could be readily injected
as a viscous solution and subsequently undergo rapid cross-
linking via autoxidation reaction mediated by oxygen species
released from oxidized gallol groups and innate oxidative
enzymes (e.g., endogenous peroxidases) even without cross-
linking agents, enabling long-term stable volumetric tissue
augmentation (Figure 1a). Here, we also explored the
mechanism of in vivo cross-linking of the SC-HA hydrogel
by gallol oxidation and demonstrated its extraordinary
properties as a dermal filler for successful application in
volumetric tissue augmentation. The SC-HA filler was
validated as a functional alternative that overcomes the
Figure 1. Preparation and characterization of the SC-HA hydrogel. (a) Schematic illustration demonstrating the in vivo cross-linking mechanism of
the SC-HA hydrogel via autoxidation of gallol groups by endogenous peroxidase in tissues and hydrogen peroxide (H2O2) generated from oxidized
SC-HA for volumetric tissue augmentation. (b) Gross view of SC-HA before and after gelation. Gelation kinetics of the SC-HA hydrogel (c)
without or (d) with horseradish peroxidase (HRP). The dashed lines indicate the time of hydrogel formation when G′ (elastic modulus) and G″
(viscous modulus) crossed. (e) Change in absorbance value at 440 nm of SC-HA solution with (red) or without (blue) HRP over time (n = 3). (f)
Quantification of generated H2O2 during the gelation process of SC-HA with (red) or without (blue) HRP (n = 3). Catechol-conjugated HA
(CA−HA) was used as a control. (g, h) In vitro biocompatibility test by Live/Dead staining of human dermal fibroblasts (HDFs) encapsulated in
the SC-HA hydrogel (cross-linked by 0.06 U mL−1 HRP) after 1 and 7 days of culture. Scale bar is 100 μm. (i) Elastic modulus at 1 Hz and
elasticity (tan δ, G″/G′) of SC-HA hydrogels (n = 4, **; p < 0.01, compared to the SC-HA group).
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limitations of conventional monophasic and biphasic HA fillers
in terms of injectability, biocompatibility, adhesiveness, and
long-term performance.
■ EXPERIMENTAL SECTION
Synthesis and Cross-Linking of SC-HA. SC-HA was synthe-
sized by conjugating a gallol moiety to the HA backbone as we
previously described.39 Briefly, HA (molecular weight 200 kDa and 1
MDa; Lifecore Biomedical, Chaska, MN) was fully dissolved (1%, w/
v) in triple-distilled water (TDW). 1-(3-Dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC; Thermo Fisher Scientific,
Watham, MA) and N-hydroxysuccinimide (Sigma-Aldrich, St. Louis,
MO) were added at molar ratios of 1.5:1 and 1:1 to HA, respectively,
and reacted for 30 min. Then, 5′-hydroxydopamine (Sigma-Aldrich)
was added at a molar ratio of 1:1 to HA, and the pH was adjusted to
4.5. After an overnight reaction, the reactant was dialyzed in acidic
phosphate-buffered saline (PBS, pH 4.5) and TDW using a Cellu-Sep
dialysis membrane (Membrane Filtration Products Inc., Seguin, TX)
with a 6−8 kDa cutoff, to remove unreacted chemicals. The resulting
conjugate was lyophilized and stored at −80°C until use. Catechol-
modified-HA (CA−HA) was synthesized as previously described.32
To confirm the conjugation of the gallol group, the synthesized SC-
HA conjugate was dissolved in deuterium oxide (Sigma-Aldrich) and
then analyzed using proton nuclear magnetic resonance (1HNMR)
spectroscopy at 300 MHz (Bruker, Billerica, MA). The conjugation
efficiency, expressed as the ratio of the modified carboxyl group in HA
unit with the gallol group, was calculated by dissolving the SC-HA
conjugate (1 mg mL−1) in acidic PBS (pH 5) and measuring the
absorbance at 280 nm using ultraviolet−visible (UV−vis) spectros-
copy (JASCO Corporation, Tokyo, Japan). Serially diluted 5′-
hydroxydopamine (maximum concentration 1 mg mL−1) was used
to construct a standard curve. To initiate cross-linking, the SC-HA
conjugate was dissolved in PBS under ambient air condition, and
horseradish peroxidase (HRP, 0.06 U mL−1; Sigma-Aldrich) was
added to the dissolved conjugate solution to model the peroxidase-
mediated oxidation occurring in vivo. The change in the absorption
spectrum during gelation was examined by using UV−vis spectros-
copy (JASCO Corporation) at predetermined time points (1, 10, and
60 min and 3, 6, 12, and 24 h). In all experiments, SC-HA was
dissolved at a concentration of 2% (w/v), and 0.06 U mL−1 HRP
(final concentration) was used, unless otherwise stated. Because the
dissolution of the SC-HA conjugate would affect homogenous
gelation and subsequent in vivo cross-linking of SC-HA,41 the
dissolution process was optimized to minimize unwanted oxidation of
the SC-HA conjugate before injection. In brief, SC-HA solution was
vigorously vortexed for 10 min to promote dissolution of the SC-HA
conjugate in PBS, centrifuged to remove bubbles in the pregel
solution, and immediately used for analyses or injection experiments.
Quantification of Hydrogen Peroxide (H2O2). The SC-HA
conjugate was dissolved at 2% (w/v) concentration in PBS (Sigma-
Aldrich) and was either not supplemented or supplemented with HRP
(0.06 U mL−1). Aliquots of 50 μL were added to conical tubes. CA−
HA dissolved in PBS at 2% (w/v) concentration was used as a
control. After cross-linking in ambient air condition, 100 μL of 0.2 M
hydrochloride (Sigma-Aldrich) solution was added to the tubes to
stop the autoxidation process at predetermined time points. After
incubation at room temperature for 30 min, the samples were stored
at −20°C until analysis. The amount of generated H2O2 was
calculated using a Pierce quantitative peroxidase assay kit (Thermo
Fisher Scientific).
Rheometric Analysis and Adhesiveness Measurement. A
commercially available biphasic HA filler composite (Restylane
Perlane Lidocaine; Q-Med, Uppsala, Sweden) was used as a control.
A rotating rheometer (Anton Paar, Ashland, VA) was used to evaluate
oscillatory rheological properties. To observe the gelation kinetics of
SC-HA hydrogels, the conjugate was immediately dissolved in PBS
(2%, w/v) that was not supplemented or supplemented with HRP
(0.06 U mL−1) and placed between the plate and probe. The storage
modulus (G′) and loss modulus (G″) were recorded in a time sweep
mode (strain: 10%; frequency: 1 Hz). The viscoelastic modulus of the
SC-HA hydrogel and the conventional HA filler was determined by
measuring G′ and G″ in a frequency sweep mode (strain: 10%;
frequency: 0.1−1 Hz). For the evaluation of the in vitro-cross-linked
hydrogel, the SC-HA conjugate dissolved in PBS (2%, w/v) in the
absence or presence of HRP (0.006, 0.06, 0.6, or 6 U mL−1) was self-
cross-linked for 3 h in a humidified chamber to prevent the hydrogels
from drying during gelation. The viscoelastic modulus of the in vivo-
cross-linked SC-HA hydrogel (2%, w/v) was examined using the
retrieved hydrogel constructs from subcutaneous spaces of ICR mice
(OrientBio, Seongnam, Gyeonggi-do, Korea) at several time points.
The value of G″/G′ at 1 Hz was defined as elasticity (tan δ). The
viscosities of PBS, commercial HA filler, and SC-HA filler (2%, w/v)
were measured in the steady shear sweep mode (0.1−1000 s−1) using
a rheometer (Anton Paar). To compare the adhesiveness of the SC-
HA hydrogel (2%, w/v) cross-linked with HRP (0.06 U mL−1) and
the commercial HA filler, the samples were placed between mouse
skin tissues tightly attached to a base plate and probe, and the
detachment stress was recorded using the tack test mode of a
rheometer (Anton Paar) by pulling the probe at a speed of 10 μm s−1.
For the lap shear test, skin tissues (1 cm × 1 cm) were fixed on glass
slides, and each filler composite was placed between tissues. After 3 h
of incubation in a humidified chamber, the shear strength was
measured using an OTT-001 universal testing machine (UTM)
(Oriental TM, Siheung, Korea) by pulling the glass slides at a rate of 1
mm s−1.
Swelling Test. To evaluate the swelling property of HA hydrogels,
fully cross-linked CA−HA and SC-HA hydrogels (2%, w/v) were
incubated in PBS at 37 °C and retrieved for measuring the weight at
several time points. SC-HA hydrogels were cross-linked in the
absence or presence of HRP (0.06 or 0.6 U mL−1). The swelling ratio
was calculated by the following formulation: (Wt − Wi)/Wi × 100,
where Wt and Wi represent the weight of the hydrogel at each time
point and the weight of the hydrogel before immersion in PBS,
respectively (n = 3−4).
Cell Culture. The biocompatibility of the SC-HA hydrogel filler
was evaluated by culturing human dermal fibroblasts (HDFs) in the
hydrogels. For cell encapsulation, HDFs were mixed with 2% (w/v)
SC-HA pregel solution (in PBS) supplemented with HRP (0.06 and
0.6 U mL−1) at a density of 1 × 107 cells mL−1. The pregel solution
was allowed to undergo autoxidation in a humidified ambient air
condition at 37 °C. The fully cross-linked hydrogels were incubated in
Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific)
supplemented with 10% (v/v) fetal bovine serum (Thermo Fisher
Scientific) and 1% (v/v) penicillin/streptomycin (Gibco, Gaithers-
burg, MD). After 1 and 7 days of in vitro culture, cells in SC-HA
hydrogels were stained with a Live/Dead viability/cytotoxicity kit
(Invitrogen, Carlsbad, CA) and visualized by fluorescence microscopy
using a model IX71 microscope (Olympus, Tokyo, Japan). The
viability of the encapsulated cells was calculated by image-based
counting of live (green) and dead (red) cells.
Injectability Test. The injectability of each HA filler was
evaluated by comparing the force required for injection. Briefly, the
SC-HA conjugate (200 K, 1 M) dissolved in PBS (2%, w/v) and the
commercial biphasic HA filler (Restylane, 1 M) were used to
individually fill a 1 mL syringe of different needle gauges (25, 27, 29,
or 30 G). The extrusion force was measured by UTM with a 10 kg
load cell. The syringes containing each filler composite were
compressed by a cylindrical bar that was fixed on the UTM with a
customized immovable jig, and the probe was moved at a rate of 12.5
mm s−1. The break loose force was defined as the force needed to
initiate the movement of plunge, and the dynamic glide force was
considered as the force needed to sustain the movement of plunge
after the initiation of movement.
In Vivo Experiment with HA Filler. To inject each filler
composite, 5 week-old ICR hairless male mice (OrientBio) were
anesthetized with ketamine (100 mg kg−1, Yuhan, Seoul, Korea) and
xylazine (20 mg kg−1, Bayer Korea, Ansan, Korea). One hundred
microliters of the commercial HA filler (Restylane, 1 M) or the SC-
HA hydrogel filler (200 K, 1 M) (2% (w/v) conjugate dissolved in
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PBS) were injected into subcutaneous spaces of mice. To monitor the
displacement of the HA filler composite, the center of each filler at the
initial injection site was marked and tracked every week for 4 weeks.
The displacement distance was determined by calculating the distance
from the initial position at several time points using ImageJ software
(National Institutes of Health, Bethesda, MD). In vivo retention and
long-term stability of the injected HA fillers were examined by
measuring the wet weight and dimensions with an electronic scale and
caliper rule, respectively, after carefully retrieving the filler constructs
at predetermined time points (0, 1, and 2 weeks, and 1, 2, 3, 6, and 12
months). The volume (V) of the retrieved fillers was calculated as V =
4π/3 × length × width × height. Remnant volume and weight were
normalized with those at the initial time point. In vivo
biocompatibility of the injected SC-HA filler was confirmed by
histological analysis. The extracted samples were fixed with 4% (w/v)
paraformaldehyde (Sigma-Aldrich), embedded in paraffin, sectioned
(6 μm thick), and stained with hematoxylin and eosin (H&E) and
toluidine blue to check the inflammatory response. The samples were
also stained with primary antibodies against keratin 5 (1:100 dilution,
Abcam, Cambridge, U.K.) and F4/80 (1:100 dilution, Abcam) and
then immunofluorescently stained with Alexa 488- or 594-conjugated
secondary antibodies (1:200 dilution, Invitrogen). The counter-
staining for cell nuclei was conducted with 4′,6-diamidino-2-
phenylindole (Vector Laboratories, Burlingame, CA).
Wrinkle Study. A mouse model of wrinkles was used. Wrinkling
was induced by treating 6 week-old ICR hairless mice (Orientbio)
with calcitriol (1α,25-dihydroxyvitamin D3, Sigma-Aldrich). Calcitriol
solution (0.2 μg dissolved in 100 μL of ethanol) was gently spread on
mouse dorsal skin five times a week for 6 weeks. After 2 weeks of
recovery, commercial HA filler (Restylane), SC-HA filler [2% (w/v)
dissolved in PBS], and SC-HA filler supplemented with epidermal
growth factor (EGF, 10 μg per injection; R&D Systems, Inc.,
Minneapolis, MN) were subcutaneously injected for tissue
augmentation and wrinkle correction. Wrinkle images were acquired
using a charge-coupled device camera (12 MP, f/1.8, Largan
Precision, Taichung, Taiwan) before and after filler injection, and
wrinkle surface area was evaluated by using an image analysis program
(ImageJ, National Institutes of Health, Bethesda, MD). The taken
images were also used for scoring evaluation according to the
classification criteria established from a previous study (0, no
wrinkles; 1, just perceptible wrinkles; 2, mild and shallow wrinkles;
3, moderate deep wrinkles; 4, deep wrinkles with well-defined edges;
5, severe and very deep wrinkles with redundant fold).42 The
randomized images of each group (n = 6−8) were exposed without
any information about the group, and the scores from the blinded
investigators (n = 15) were averaged for the assessment. For further
evaluation of wrinkle correction, wrinkle morphology was replicated
using silicone-based replicas (Silflo; J&S Davis, Stevenage, U.K.)
before and after filler injection and was analyzed using a Visioline VL
650 skin visiometer (Courage-Khazaka Electronic GmbH, Koln,
Germany). Imaging of the wrinkle surface and quantitative indexes
including area, length, and depth were evaluated using the
Quantirides system (Monaderm, Monaco, France). To check the
effect of the EGF-incorporating SC-HA filler, skin tissue adjacent to
the injected HA filler was examined with H&E and Masson’s
Trichrome staining 1 month after the injection.
Growth Factor Release Test. To check growth factor release
from SC-HA hydrogels, recombinant human EGF protein (R&D
Systems) was added into the SC-HA pregel solution, cross-linked in
the presence of HRP (0.6 U mL−1), and then the resultant hydrogels
containing EGF were incubated in PBS at 37 °C. The final
concentration of the hydrogel was 2% (w/v), and 10 μg of EGF
was incorporated within the hydrogel. To gradually degrade the SC-
HA hydrogel, 0.5 U mL−1 hyaluronidase (Sigma-Aldrich) was treated
during the incubation. PBS was harvested at predetermined time
points (8 h, day 1, day 2, day 3, day 5, and day 7), and the released
EGF in the retrieved PBS was quantified using an enzyme-linked
immunosorbent assay (ELISA) kit for human EGF (Duo Set, R&D
Systems) following the manufacturer’s instruction.
Statistical Analysis. All of the quantitative data are presented as
mean ± standard deviation. Statistical analysis was performed with
GraphPad Prism 5 software (GraphPad Software, San Diego, CA)
using unpaired Student’s t-test. Differences between groups
represented by p-values <0.05 and 0.01 were considered statistically
significant.
■ RESULTS AND DISCUSSION
The gallol modification of the SC-HA hydrogel resulted in the
formation of a cross-linker-free HA hydrogel by enzymatic
autoxidation. The SC-HA conjugate (200 kDa HA) was
synthesized by coupling gallol-containing 5′-hydroxydopamine
to the HA backbone by carbodiimide chemistry (Figure S1a).
The success of the conjugation was confirmed by 1H NMR
spectroscopy, which demonstrated newly detected peaks at 2.8
and 6.5 ppm. The peaks represent ethyl protons (between
gallol and amine groups) and aromatic protons (Figure S1b).
The conjugation efficiency, defined as the ratio of the modified
HA unit with the gallol group, was 8.3%. The stable SC-HA
hydrogel was formed by merely dissolving the conjugate in
neutral PBS (pH 7.4) at 2% (w/v) concentration, without
addition of any catalysts or change of physiological conditions,
such as pH and temperature (Figure 1b). Through the
autoxidation of the SC-HA conjugate in a pregel solution, the
oxidized gallol groups gradually cross-linked themselves, and
the resultant hydrogel was formed approximately 13 min after
the dissolution in PBS, which was indicated by the cross-over
time between G′ (elastic modulus) and G″ (viscous modulus)
(Figure 1c). Given that endogenous peroxidases in tissue and
body fluid can act as catalytic enzymes for autoxidation when
the pregel solution of SC-HA is administered in vivo,40 HRP
was used as a model enzyme to recapitulate the cross-linking
process in vivo. Addition of HRP (0.06 U mL−1) to the SC-HA
pregel solution shortened the cross-linking time to 5 min
(Figure 1d), supporting our hypothesis of the accelerated
gelation kinetics of SC-HA by enzymatic autoxidation. UV−vis
spectroscopy analysis was also performed to evaluate the cross-
linking mediated by gallols within the hydrogel. After initiating
auto-cross-linking of the SC-HA conjugate, there was a gradual
increment of absorbance in a broad range from 280 to 440 nm,
resulting from various oxidative intermediates and purpur-
ogallins formed by the dimerization of gallols (Figure S2).
When HRP was supplemented in the SC-HA pregel solution,
the overall absorbance value was increased much faster than
that of SC-HA without the enzyme, indicating accelerated
autoxidation by the enzymatic catalyst (Figure S2b).
Especially, the higher level of absorbance at 440 nm indicated
the enhanced autoxidation and formation of bicyclic products
in the presence of HRP (Figure 1e).43,44
The SC-HA conjugate with the gallol group possesses
sufficient oxidative potential to initiate self-cross-linking and
further accelerates the oxidative cross-linking process through
self-production of oxidants. Although the polymer conjugates
modified with other phenolic moieties (e.g., tyrosine, catechol)
can also form the hydrogels via HRP-mediated cross-linking,
oxidants like peroxide should be additionally supplemented to
initiate oxidation reactions for cross-linking.45−47 In contrast to
the phenolic moieties with two hydroxyl groups, the gallol
oxidation chemistry has an important unique feature: H2O2 is
produced as a byproduct during gallol autoxidation, and the
generated peroxides serve as oxidants to accelerate the
subsequent oxidation reaction of the unreacted gallol groups.40
To observe this mechanistic role of the gallol group in SC-HA
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hydrogel formation, H2O2 generation during the incubation at
room temperature was quantified. In this experiment, catechol-
conjugated HA (CA−HA) (8.8% of catechol conjugation)
with lower oxidative potential served as a control hydrogel
system. As expected, the CA−HA conjugate generated a
negligible amount of H2O2 (0.6 μM) during 24 h (Figure 1f).
In contrast, the total generated H2O2 in the SC-HA group was
81.7 μM, which was significantly greater than the amount in
the CA−HA group (Figure 1f). Interestingly, the addition of
HRP to SC-HA increased H2O2 production during the first 2
h, probably due to the HRP-mediated facilitation of the
oxidation process. From 2 h onward, H2O2 production in the
SC-HA group with HRP was constantly lower (61.4 μM for 24
h) than that of the SC-HA group without HRP (Figure 1f),
indicating that the generated H2O2 was successively consumed
by peroxidase for continuous autoxidation. Although the CA−
HA conjugate is useful for injectable adhesive hydrogels, it
mostly needs additional cross-linkers (e.g., Fe3+ ions, sodium
periodate, or HRP with H2O2) for inducing oxidative cross-
linking of the hydrogels. As shown in Figure 1f, CA−HA could
not generate oxygen species capable of initiating self-cross-
linking to form the HA hydrogel, while the SC-HA conjugate
with gallol moieties could spontaneously generate H2O2 due to
its greater oxidative potential, thereby providing an in situ
cross-linkable hydrogel system with no need of supplementary
cross-linkers. Given that when H2O2 generated by gallol
autoxidation was consumed in the presence of peroxidase,
dimerization of quinone intermediates of oxidized gallols was
further promoted (Figures 1e,f, and S2), thus accelerating the
cross-linking reactions to form the SC-HA hydrogel, gelation
kinetics of the SC-HA hydrogel increased by autoxidation
(Figure 1c,d) seems to be coordinated with the peroxidase-
mediated coupling reaction.
The oxidation reaction by peroxidase to form the SC-HA
hydrogel is highly biocompatible and also improves the
mechanical property of the hydrogel. To evaluate the
biocompatibility of the SC-HA hydrogel, HDFs were mixed
with the SC-HA pregel solution (2%, w/v), and the cell-
containing solution was cross-linked by treatment with HRP
(0.06 and 0.6 U mL−1). Live/Dead cytotoxicity staining
revealed that most of the encapsulated cells in the SC-HA
hydrogel were viable after 1 and 7 days of in vitro culture,
regardless of the HRP concentration [day 1: 97.3 ± 1.1% (0.06
U mL−1) and 95.3 ± 0.4% (0.6 U mL−1); day 7: 94.5 ± 1.0%
(0.06 U mL−1) and 92.3 ± 1.4% (0.6 U mL−1)] (Figures 1g,h
and S3). Although H2O2 produced during SC-HA gelation can
reduce cellular metabolic activity at high concentrations, our
SC-HA hydrogel system showed minimal cytotoxicity. This
was probably due to the low amount of H2O2 that was
generated, which may not induce apoptotic cell death, and the
continuous H2O2 consumption needed for the autoxidation
reaction.48 SC-HA cross-linking upon the addition of HRP
altered the mechanical properties of the resultant HA hydrogel.
The SC-HA hydrogel formed in the presence of HRP exhibited
a significantly higher elastic modulus (64.0 ± 7.3 Pa) than the
hydrogel formed without HRP (22.1 ± 4.3 Pa) (Figure 1i).
Moreover, the elasticity (tan δ = G″/G′) was lower in SC-HA
hydrogels formed with HRP than in hydrogels formed without
HRP (SC-HA; 0.41 ± 0.06 vs SC-HA/HRP; 0.17 ± 0.01),
indicating that elasticity was significantly increased by the
addition of enzymes (Figure 1i). The improved mechanical
property and elasticity are crucial for long-term stability of the
injected hydrogel construct.23,49 The collective observations
support the assumption that the self-cross-linking process of
the SC-HA conjugate that is accelerated by inherent
peroxidase in vivo after injection would be biocompatible
and provide long-term stability of the filler construct with
improved mechanical properties. Although the concentration
and activity of peroxidase (0.06 and 0.6 U mL−1) may not be
identical to those of the in vivo environment (e.g., 0.44 and
1.32 U g−1 glutathione peroxidase activity in human and mouse
dermis tissues, respectively),50,51 the HRP-mediated oxidative
model could provide an effective in vitro system to recapitulate
in vivo self-cross-linking of the SC-HA hydrogel. HRP addition
was confirmed to accelerate oxidative cross-linking of SC-HA
by promoting dimerization of oxidized gallols following self-
production of oxygen species (Figures 1e,f, and S2), finally
leading to faster gelation and improved mechanical properties
of hydrogels (Figure 1c,d,i). Further rheometric investigation
with a wider range of HRP activity (0.006, 0.06, 0.6, and 6 U
mL−1), which may cover varied concentrations and activities of
endogenous peroxidase in different tissues and in vivo
situations, indicated that the elastic modulus and elasticity of
the SC-HA hydrogel were gradually increased proportional to
an increase in HRP activity up to 6 U mL−1 (Figure S4).
The SC-HA hydrogel possesses improved physical proper-
ties over previously reported tissue adhesive HA hydrogels
such as the CA−HA hydrogel due to increased cross-linking
density (Figure S5). During incubation of HA hydrogels under
physiologically relevant conditions (in PBS at 37 °C), the
weight of the CA−HA hydrogel increased more than 200%
from its original state after 3 days and then further swelled up
to 240% on day 7 of incubation, whereas the swelling level of
SC-HA hydrogels was generally low (10−50%), which reached
a plateau after 1 day of incubation. This result may indicate
that the cross-linking density of the SC-HA hydrogel is greater
than that of the CA−HA hydrogel. Oxidative gallol cross-
linking seems to induce formation of more robust
intermolecular polymeric networks in HA hydrogel constructs
than the cross-linking reaction between oxidized catechol
groups. Notably, the SC-HA hydrogel cross-linked via
autoxidation without HRP addition showed a similar swelling
ratio (48.2% on day 7 of incubation) to that of a previously
reported gallol-modified HA hydrogel cross-linked by an
oxidant (NaIO4).
39 With the increase of HRP concentration
from 0.06 to 0.6 U mL−1, a lower swelling of the SC-HA
hydrogel was observed, indicating increased cross-linking
density of the hydrogels proportional to enzymatic activity
for oxidation.
Next, we evaluated the injectability of the SC-HA filler using
different-sized needles. The injection force of the dermal filler
is affected by rheological and physiochemical properties of the
filler composite, which include viscosity, particle size, cross-
linking density, and polymer concentration.20 In particular, the
use of conventional dermal fillers containing large particulates
(>400 μm) or having high viscosity for stable deep-tissue
applications usually requires large needles (23−27 G);
otherwise, high pressure during injection is inevitable.49 High
pressure during injection is undesirable, since it may push
small vessels or nerves near the injection site, resulting in
devastating complications associated with vascular damage and
nerve block.52 In addition, the larger perforation by large
needles increases the frequency of pain, bleeding, and
subsequent infection.53,54 Therefore, dermal filler should be
injectable without high pressure, even when small-gauge
needles are used, to avoid pain and potential complications.
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A commercially available and representative biphasic, chemi-
cally cross-linked HA (CC-HA) filler product (Restylane),
which is cross-linked by BDDE without HRP, was used as a
control for the comparison of filler injectability. Inhomoge-
neous HA particulates (400−1000 μm in size) were observed
within the CC-HA filler, while there were no aggregated
constructs in the SC-HA filler solution (Figure 2a). To
measure the force during injection with a universal testing
machine, each filler composite was loaded in a 1 mL syringe
and pressed with an injection speed of 12.5 mm s−1 using 25,
27, 29, and 30 G needles. In the SC-HA group, viscous
liquidlike composites could be smoothly injected, regardless of
the molecular weight of HA (200 kDa and 1 MDa). There was
a slight increase in the extrusion force when smaller needles
(29 and 30 G) were tested for the injection of the 1 M SC-HA
filler (Figure 2b). However, the CC-HA filler composite
required a much larger injection force than the SC-HA filler
because the size of the particle-based filler composite exceeded
the inner diameter of needles (<400 μm) (Figure 2b). In
addition, we measured the break loose force (Figure 2c) and
dynamic glide force (Figure 2d), which is the force needed to
initiate the movement of the plunger and the force required to
Figure 2. Injectability of SC-HA hydrogel fillers. (a) Microscopic and macroscopic views of CC-HA filler (upper) and SC-HA filler (lower)
composites. (b) Profiles of extrusion force of CC-HA and SC-HA (200 K, 1 M) fillers in various-sized needles (25, 27, 29, 30 G). (c) Break loose
force (the force needed to initiate the movement of plunge) and (d) dynamic glide force (the force needed to sustain the movement of plunge).
CC-HA filler and SC-HA fillers (200 K, 1 M) were tested with different gauge needles (n = 4). (e) Viscosities of PBS, CC-HA filler, and SC-HA
hydrogel solution as a function of time.
Figure 3. Tissue adhesion and displacement of SC-HA fillers. (a) Adhesion of the CC-HA filler and the SC-HA hydrogel filler on the skin tissue
after 1 month of injection into the subcutaneous regions of mice. (b) Lap shear test for comparing shear strength of the CC-HA filler and the SC-
HA hydrogel filler placed between mouse skin tissues and (c) average maximum shear strength of each filler composite (n = 3, **; p < 0.01,
compared to the CC-HA group). (d) Tack test to measure the detachment force of the CC-HA filler and the SC-HA hydrogel filler placed between
mouse skin tissues and (e) average adhesion strength of each filler composite (n = 3). For in vitro formation of SC-HA hydrogel, 0.06 U mL−1 HRP
was added to a 2% (w/v) SC-HA pregel solution. (f) Displacement of the CC-HA filler and the SC-HA hydrogel filler during the 4 weeks after
subcutaneous injection. (g) Diagram demonstrating the location of each filler construct displaced from the initial site (center of the diagram) and
(h) average distance from the initial site 4 weeks after the injection (n = 8, **; p < 0.01, compared to the CC-HA group). (i) Cumulative
displacement distance during 4 weeks after the injection (n = 8).
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sustain the movement of the plunger, respectively. Both the
200 K and 1 M SC-HA fillers exhibited a low break loose force
with all of the needles. However, the CC-HA filler required a
significantly larger break loose force, especially when small-
gauge needles (29 and 30 G) were used for injection (Figure
2c). The SC-HA filler with the 200 K HA backbone had a
constantly low dynamic glide force irrespective of the needle
size (Figure 2d). Although the SC-HA filler with a larger
molecular weight (1 M) needed a somewhat higher dynamic
glide force as the needle size decreased (29 and 30 G), the CC-
HA filler required a significantly larger dynamic glide force,
compared with the SC-HA filler (Figure 2d). We also found
that the viscosity of SC-HA dissolved in PBS gradually
increased due to cross-linking by autoxidation in the ambient
air condition, but the value (50−200 mPa s) was significantly
lower than that of the CC-HA filler with a viscosity over
50 000 mPa s (Figure 2e). From these results, we could
conclude that the dermal injectability of SC-HA fillers is
superior to that of CC-HA fillers, which significantly reduces
pain, bleeding, and tissue damage in clinical situations.
In addition to their poor injectability, a critical limitation of
commercial biphasic CC-HA fillers is that filler displacement
often occurs from the original injected site by external force,
gravity, and daily muscular movement. The migration of the
injected filler constructs or their parts to unwanted positions
may produce complications, such as inflammation at a location
distal from the injected site, which requires additional and
complicated processes including repositioning, reinjection, and
even removal of the constructs in emergent situations.55,56
Given the robust affinity of oxidized gallol moieties to various
proteins, the gallol-modified hydrogels could exhibit excellent
tissue adhesion, even when wet.37−39 We have previously
demonstrated that formation of various quinone intermediates
and bicyclic products during oxidation of gallol groups enables
strong adhesion of the gallol-modified hydrogel to a tissue
surface.39 Indeed, when the filler composites were harvested
with adherent skin tissues 1 month after injection into
subcutaneous spaces of mice, the SC-HA fillers tightly adhered
to the skin tissue, while commercial CC-HA fillers weakly
interacted with surrounding skin tissues and barely attached to
the tissue (Figure 3a). To measure the adhesion strength, SC-
HA pregel solution [2% (w/v) in PBS] supplemented with
HRP (0.06 U mL−1) was placed between mouse skin tissues
anchored on glass slides and then fully cross-linked for 3 h in a
humidified chamber. The subsequent lap shear test revealed
that the shear strength of the SC-HA filler (2.07 ± 0.66 kPa)
was 7.6-fold greater than that of the CC-HA filler (0.27 ± 0.08
kPa), indicating that the SC-HA filler was more resistant to
Figure 4. In vivo application of SC-HA fillers for safe, long-lasting volumetric tissue augmentation and wrinkle correction. (a) Gross view of the
tissue volume before and after SC-HA filler injection. Dashed line indicates newly augmented tissue by SC-HA hydrogel filler injection. (b) Elastic
modulus (at 1 Hz) of SC-HA filler composite retrieved at predetermined time points after subcutaneous injection (n = 3). CC-HA filler composite
retrieved after 2 days was used as a control. (c) Histological analysis with H&E, toluidine blue, and immunofluorescence (keratin 5, red; F4/80,
green; nuclei, blue) staining of SC-HA fillers adjacent to skin tissues 1 and 7 days after subcutaneous injection. Dashed lines indicate the boundary
between tissues and the injected filler composites. Scale bar is 200 μm. (d) CC-HA filler composites and SC-HA fillers (200 K, 1 M) retrieved at
predetermined time points up to 12 months after injection into subcutaneous space of mice. (e) Volume and (f) weight of the remaining filler
constructs harvested at each time point (n = 4−8). (g) Gross view of wrinkles on mouse skin before and after tissue augmentation by HA filler
injection. Control group is a normal mouse skin without wrinkle induction. (h) Scoring evaluation and (i) mean surface area of wrinkles before and
after SC-HA and CC-HA filler injection (n = 6−8, **; p < 0.01, compared to before the injection of each filler).
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displacement than the commercial CC-HA filler (Figure 3b,c).
The detachment stress of HA fillers from mouse skin tissue was
also measured using a rheometer in the tack test mode. The
adhesion strength was higher in the SC-HA filler group (0.51
± 0.32 N) than in the CC-HA filler group (0.12 ± 0.01 N)
(Figure 3d,e), consistent with the lap shear test result.
The excellent tissue adhesive property of the SC-HA
hydrogel would allow for the stable and long-term retention
in vivo of the injected HA filler, which cannot be achieved with
conventional CC-HA filler systems. The fixability of the SC-
HA filler was further evaluated by monitoring the movement of
the injected filler constructs in subcutaneous spaces of mice.
Four weeks after injection, most of the CC-HA filler constructs
were displaced from where they were first injected, but the SC-
HA fillers remained around the injection site (Figure 3f). The
final distance from the initial position of the injected filler
composite indicated that displacement was significantly
prevented in the SC-HA filler group compared with that in
the CC-HA filler group (CC-HA: 0.68 ± 0.2 cm; SC-HA: 0.2
± 0.11 cm) (Figure 3g,h). The cumulative migration distance
during the 4 weeks of observation also demonstrated the
retention of SC-HA fillers at the desired position in contrast to
CC-HA fillers (Figure 3i). Based on its excellent tissue
adhesiveness, the SC-HA hydrogel filler could be stably
maintained at the original injection site with minimal
migration.
Finally, the cosmetic application of the SC-HA hydrogel
filler was demonstrated for volumetric tissue augmentation and
wrinkle correction. The SC-HA pregel solution at 2% (w/v)
concentration was injected using a 30 G syringe into
subcutaneous regions of mice. The injected SC-HA pregel
solution devoid of cross-linking agents formed three-dimen-
sional hydrogel filler constructs via autoxidation in vivo
approximately 10 min after injection. The shape of the SC-
HA filler could be easily adjusted before the formation of a
fully cross-linked hydrogel, and volumetric augmentation was
clearly observed at the injected site (Figure 4a). The in vivo
cross-linking to form robust SC-HA hydrogel fillers was
confirmed by measuring the mechanical property of the HA
filler constructs retrieved at several time points after injection
into the subcutaneous space (Figure 4b). Interestingly, the
elastic modulus (G′) of the SC-HA hydrogel filler (200 kDa
HA) 30 min after injection (93.7 Pa) was higher than that of
the SC-HA hydrogel prepared via in vitro oxidative cross-
linking by HRP (64.0 Pa). The G′ of the SC-HA hydrogel
further increased to 644.7 Pa 1 h after injection and remained
at similar levels for the next 2 days. Although the SC-HA filler
was injected as a viscous solution without any cross-linking
agents, gallol oxidation mediated by endogenous enzymes (e.g.,
peroxidases) that were abundant in subcutaneous tissue
induced in vivo cross-linking of SC-HA, successfully generating
stable and robust hydrogel constructs with comparable
mechanical properties to conventional biphasic CC-HA filler
composites (Figure 4b). To evaluate inflammation by the SC-
HA filler, injected SC-HA hydrogels attached to surrounding
tissues were stained using H&E and toluidine blue (Figure 4c).
These histological analyses revealed that the injection and in
vivo cross-linking of the SC-HA hydrogel did not trigger any
significant infiltration of inflammatory cells within or around
the hydrogel constructs 1 and 7 days after the injection,
indicating the excellent biocompatibility of the SC-HA filler.
The immunostaining against F4/80 revealed that few macro-
phages were detected within or around the SC-HA hydrogel
filler constructs 1 and 7 days after injection into the
subcutaneous space of mouse (Figure 4c), which indicates
that injection of the SC-HA hydrogel did not evoke any
significant inflammation, confirming the biocompatibility of
the SC-HA filler again.
Most importantly, the SC-HA hydrogel showed excellent
performance as an injectable dermal filler for tissue
augmentation, wrinkle correction, and long-term volumetric
maintenance. Longevity of the injected filler is another
important requirement for patients to minimize cost and
retain the long-term effect of the filler. To evaluate the in vivo
retention of HA fillers, SC-HA fillers (200 K and 1 M) and
CC-HA filler composites (1 M) were subcutaneously injected
and retrieved at several time points up to 1 year to examine
physiochemical changes in volume and weight of the
constructs. In the CC-HA filler group, the constructs gradually
degraded, and only about 50% of the initial volume and weight
remained 3 months after injection, and nearly 80% of the
injected filler was eliminated 1 year after injection (Figure 4d−
f). However, our SC-HA filler constructs were well maintained
without significant reduction in volume and weight for 1 year,
regardless of molecular weight, demonstrating the potential of
the SC-HA hydrogel as a safe, long-term stable injectable filler
for volumetric augmentation (Figure 4d−f). The functionality
of the SC-HA filler for wrinkle correction was assessed in a
mouse model of wrinkles. Formation of wrinkles in mouse skin
was chemically induced by treatment with calcitriol solution
for 6 weeks.29 Injection of the SC-HA filler under the wrinkled
skin tissue resulted in tissue augmentation and wrinkle
correction (Figure 4g). The surface morphology of the
wrinkled skin tissue was visualized using a skin visiometer.
The replica image revealed that the SC-HA filler clearly
reduced wrinkles on mouse skin (Figure 6Sa). All of the
dimensional indexes demonstrating the level of wrinkles,
including total wrinkle area, total wrinkle length, mean wrinkle
length, and mean wrinkle depth, were significantly decreased
after injecting the SC-HA filler, indicating successful
volumetric augmentation and wrinkle correction (Figure
6Sb). For scoring evaluation, the degree of wrinkle was ranged
from 0 to 5 following the evaluation criteria described by
Lemperle et al.42 When HA hydrogel fillers were injected
under the skin tissue with chemically induced wrinkles, both
CC-HA and SC-HA fillers significantly reduced wrinkles on
the skin. The scores of corrected wrinkles by those HA fillers
were of similar levels to that of normal mouse skin without
wrinkle induction (Figure 4h). The mean surface area of
wrinkle was also significantly reduced after injecting both types
of HA fillers, indicating that the wrinkle correction by SC-HA
fillers is comparable to that by commercial CC-HA fillers
(Figure 4i).
In addition, based on the higher binding affinity of the
oxidized gallol moiety to nucleophiles in proteins, SC-HA can
provide a functional dermal filler that delivers growth factors to
enhance skin tissue regeneration in a sustained and controlled
manner. Our previous studies demonstrated that catechol- or
gallol-functionalized hydrogels can retain the encapsulated
proteins for a long time due to their ability to tether the
proteins.39,57 Thus, growth factor-containing SC-HA fillers
could allow the sustained release of proteins in vivo from the
gradually degraded HA hydrogel. The ELISA data showing the
release profiles of EGF during incubation under physiologically
relevant conditions (in PBS at 37 °C) revealed that only a
small amount of EGF (∼10% of the initially loaded EGF) was
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released from SC-HA hydrogel fillers in the absence of
hyaluronidase due to a great avidity of oxidized gallol groups to
proteins, but EGF was gradually released from SC-HA filler
constructs upon hyaluronidase treatment (Figure S7a). This
result may indicate that growth factors for skin regeneration
could be sustainedly released from SC-HA hydrogel fillers in
vivo over a long-term period, speculating the regenerative
potential of the growth factor-incorporated SC-HA hydrogel as
a functional dermal filler. We injected the SC-HA pregel
solution including EGF (10 μg dose) under a mouse skin with
chemically induced wrinkles. After 1 month of the injection,
H&E staining revealed that the SC-HA filler containing EGF
produced dermal histological morphology similar to that of
normal wrinkle-free skin (Figure S7b). Masson’s trichrome
staining indicated that collagen deposition in the dermis was
increased in the SC-HA filler group with EGF compared with
the untreated group (Figure S7b). These results suggest the
possibility of an injectable SC-HA hydrogel as a functional
dermal filler that corrects wrinkles and promotes skin
regeneration.
The SC-HA hydrogel developed herein has several novel
aspects and advantages over previously reported gallol-
modified hydrogels. The main idea of this study is to apply
gallol chemistry for a cross-linker-free injectable hydrogel filler
that is highly biocompatible and long-term stable with minimal
displacement. Several studies including ours demonstrated
gallol-conjugated polymers and their oxidative cross-linking to
form hydrogels with tissue adhesive properties. Hydrogel
formation in our current study and those previous studies was
basically mediated via the same type of reaction (oxidation of
gallols conjugated to the polymer backbone), but gallol
oxidation was induced by different cross-linking processes.
Most previous studies relied on supplementary chemical agents
(e.g., oxidants, ions) for oxidative gallol cross-linking
reactions.38,39,58,59 Gallol oxidation by additional cross-linkers
is highly efficient but sometimes induces too rapid gelation,
which impairs the injectability of hydrogels and hinders
uniform distribution of intermolecular polymer networks in the
hydrogel constructs. Thus, in the present study, we employed a
different chemical cross-linking mode by H2O2 generated by
autoxidation of gallols even in the absence of exogenous cross-
linkers, suggesting an in situ self-cross-linkable hydrogel model.
Due to self-production of oxygen species of oxidized gallols
and endogenous peroxidase-mediated coupling reaction under
in vivo conditions, we could demonstrate easily injectable HA
hydrogel filler systems without any additional cross-linkers. In
contrast to previously reported gallol-conjugated polymers
incorporated with cross-linkers, since the SC-HA conjugate
can be injected in a solution state with low viscosity, it is
readily injectable even when using small-gauge syringe needles,
thus allowing significant reduction in pain, bleeding, and tissue
damage, which is hardly accomplished with conventional
gallol-conjugated hydrogels due to rapid gelation initiated by
cross-linkers before injection. Although the final chemical
adducts by gallol oxidation reaction may be almost identical in
our current study and previous studies, different mediators are
involved in the cross-linking process, allowing us to adjust
gelation kinetics that is more feasible for injectable hydrogel
filler application. Since there is no need of cross-linkers, this
can also remove potential safety issues caused by additional
chemical cross-linkers.
More importantly, remarkably improved long-term in vivo
stability of SC-HA hydrogel fillers may be attributed to the
absence of supplementary cross-linkers such as oxidants. It has
been known that reactive oxygen species and hydroxyl radicals
can induce oxidative degradation of HA by mediating sugar
ring opening in the HA backbone.60,61 Degradation of the HA
backbone is also known to generate H2O2 as a byproduct,
62
which further accelerates oxidative opening of the HA sugar
ring. Consequently, oxidants (e.g., NaIO4) used to cross-link
gallol-modified HA may affect the degradation profiles of
hydrogels.39 As SC-HA in our current study does not require
the addition of such oxidants for gelation, the levels of reactive
oxygen species and radicals in SC-HA hydrogels are assumed
to be lower than those in gallol-modified HA hydrogels cross-
linked by exogenously added oxidants. Although H2O2 is
generated from autoxidation of gallols in SC-HA, it is most
likely to be consumed by innate peroxidase in tissues and then
used for a series of oxidative reactions for cross-linking rather
than for HA degradation. Therefore, in vivo cross-linking of
SC-HA via gallol autoxidation alone without exogenous
oxidants could minimize degradation of the HA backbone
during the gelation process, contributing to the improved long-
term stability of SC-HA hydrogel filler constructs in vivo.
Under inflammatory conditions with an increased level and
activity of reactive oxygen species and radicals, it should be
more critical to minimize oxidative degradation of HA for
long-term maintenance. Previous studies demonstrated that
chemicals (e.g., captopril, tiopronin) and enzymes (e.g.,
catalase) possessing radical scavenging activity prevent HA
oxidative degradation.60,62 A combination strategy with radical
scavenging molecules could expand the application of SC-HA
hydrogels to injured tissues with severe inflammation.
Lastly, we demonstrate the potential of the SC-HA hydrogel
as a functional dermal filler capable of mediating sustained and
controlled drug delivery for tissue regeneration (Figure S7).
Overall, the concept of in situ chemical cross-linking through
coordination of gallol autoxidation and endogenous oxidative
enzymatic reaction may be able to provide novel chemical
aspects of our SC-HA hydrogel system and facilitate
development of multifunctional biomaterials controllable in a
more sophisticated manner and highly feasible for human
translational approach.
■ CONCLUSIONS
The findings demonstrate the applicability of the gallol-
modified HA hydrogel as a self-cross-linkable filler with no
need of cross-linking agents or catalysts for cosmetic and
plastic reconstruction. The performance of our SC-HA
hydrogel as an injectable dermal filler was superior to that of
commercially available, chemically cross-linked biphasic HA
filler composites in terms of injectability, tissue adhesiveness,
and long-term volumetric augmentation. The SC-HA filler
could be smoothly injected even using small-gauge syringe
needles. The improved tissue adhesive ability and mechanical
stability of the SC-HA filler allowed for long-term retention of
the filler constructs at the original injection sites without
adverse effects. The potential mechanism of the in vivo self-
cross-linking of the SC-HA hydrogel filler may be involved in
H2O2 self-production from oxidized SC-HA and a series of
oxidative reactions facilitated by innate peroxidases in the
tissue. Our novel strategy based on a self-cross-linked hydrogel
overcomes the limitations of the current cross-linking methods
for HA-based fillers and provides a highly biocompatible, easily
injectable, and mechanically stable filler system. The catalyst-
free strategy exploited in this study could be further expanded
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to diverse biomedical applications, including cell therapy,
tissue engineering, and drug delivery, by incorporating
functional cells or specific drugs.
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